Joe Bates is a member of the Bad River Band, a Native American Tribe residing along Lake Superior in Wisconsin. He and his community have been embroiled in a long-standing legal and public relations battle against Enbridge, a Canadian energy company, to protect their ancestral lands. This struggle has been documented in "Bad River," a documentary film released in early 2024, which showcases Bates and his fellow activists within the band. Joe joins Jay to share his personal journey of activism, the profound influence of past generations of tribal and environmental activists on his own path, and the ongoing fight against Enbridge, which affects the future of water protection in America. To learn more about the Bad River Band, click here. Episode Chapters (00:00) - Intro (01:19) - Joe’s activist history (04:31) - The connection between the Bad River Band and their land (10:06) - How did Enbridge come to have pipes under native land against the Bad River Band’s wishes? (14:00) - The threat’s Enbridge’s Line 5 poses to the environment (18:10) - “You can’t put a price tag on what we have. What we have is priceless.” (19:23) - Joe and Jay discuss the documentary “Bad River” (22:58) - Thank you and goodbye For video episodes, watch on www.youtube.com/@therudermanfamilyfoundation Stay in touch: X: @JayRuderman | @RudermanFdn LinkedIn: Jay Ruderman | Ruderman Family Foundation Instagram: All About Change Podcast | Ruderman Family Foundation To learn more about the podcast, visit https://allaboutchangepodcast.com/…
Podcasts, die es wert sind, gehört zu werden
GESPONSERT
![Artwork](/static/images/128pixel.png)
1
IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
Travere Therapeutics
Listeners can expect to learn about: • The disease burden and underlying pathophysiology of IgA nephropathy, including the role of endothelin and angiotensin in disease progression • The current IgAN treatment landscape • The response to sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with IgA nephropathy in the phase 3 PROTECT trial
…
continue reading
![Artwork](/static/images/128pixel.png)
1
IgA Nephropathy: Current Treatment Landscape, Disease Burden, and 2-Year PROTECT Trial Data Supporting Sparsentan as an Emerging Treatment Option
16:11
16:11
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
16:11In this podcast, Dr Edgar Lerma and Dr Dana Rizk discuss IgA nephropathy and the key data on sparsentan from the phase 3 PROTECT trial.Von Travere Therapeutics
…
continue reading